Truvada disoproxil fumarate (a prodrug of truvada), marketed by Gilead Sciences under the trade name Viread®, belongs to a class of antiretroviral drugs known as nucleotide analogue reverse transcriptase inhibitors (nRTIs), which block reverse transcriptase, an enzyme crucial to viral production in HIV -infected people. In vivo truvada disoproxil fumarate is converted to truvada, an acyclic nucleoside phosphonate (nucleotide) analog of adenosine 5’-monophosphate.
Truvada belongs to a class of antiretroviral drugs known as nucleotide analogue reverse transcriptase inhibitors (NtRTIs), which block reverse transcriptase, an enzyme crucial to viral production in HIV-infected people. Truvada is currently in late-stage clinical trials for the treatment of hepatitis B. Truvada disoproxil fumarate is an acyclic nucleoside phosphonate diester analog of adenosine monophosphate. Truvada requires initial diester hydrolysis for conversion to truvada and subsequent phosphorylations by cellular enzymes to form truvada diphosphate. Truvada diphosphate is a weak inhibitor of mammalian DNA polymerases α, β, and mitochondrial DNA polymerase γ.
Limited clinical experience at doses higher than the therapeutic dose of truvada 300 mg is available. In Study 901 truvada disoproxil fumarate 600 mg was administered to 8 patients orally for 28 days. No severe adverse reactions were reported. The effects of higher doses are not known.
Strength: 200 Mg / 300 Mg
Pill Imprint: GILEAD 701
View Images & Details